PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)

Trial Profile

PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2018

At a glance

  • Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Jul 2018 Planned End Date changed from 30 Dec 2018 to 30 Mar 2020.
    • 19 Jul 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top